查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年心臟修復系统的全球市场
市场调查报告书
商品编码
1217589

2022-2029 年心臟修復系统的全球市场

Global Cardiac Restoration Systems Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内 (2022-2029)，心臟修復系统的全球市场规模预计将以健康的复合年增长率增长。

心臟修復系统用于治疗受损或患病的心臟瓣膜。 CVD 会影响心臟和血管，加剧冠状动脉疾病和中风等疾病，并导致动脉中出现高风险的血栓和脂肪沉积。 心臟修復系统在任何冠状动脉旁路移植术后用于重塑心室并启动外科前心室修復 (SAVER)。

市场动态

不断上升的心脏病、人口老龄化、市场发展和肥胖人口正在推动全球心臟修復系统市场。

心血管疾病的日益流行正在推动全球心臟修復系统市场的增长。

心血管疾病包括心臟和血管疾病，如冠心病、脑血管病、风湿性心脏病等。 CVD 病例的增加正在推动全球心臟修復系统市场。 例如，根据美国心臟协会的数据，CVD 在 2020 年导致全球约 1910 万人死亡。 在全球范围内，到 2020 年将有大约 2.441 亿人患有缺血性心脏病 (IHD)，据估计受影响的男性多于女性（分别为 1.41 亿和 1.031 亿）。 据世界卫生组织称，心血管疾病 (CVD) 是全世界死亡的主要原因，估计每年有 1790 万人死亡。

心脏病和中风最重要的行为风险因素是不健康的饮食、身体懒惰、吸烟和有害饮酒。 行为危险因素对患者的影响可表现为血压升高、血糖水平升高、血脂升高以及超重和肥胖。 行为风险因素的增加导致全球 CVD 增加。 根据美国心臟协会 2022 年心脏病和中风统计数据更新情况说明书全球疾病负担，估计 2020 年全球有 810 万人使用烟草（包括吸烟、二手烟和咀嚼烟草）（据了解，男性为 630 万）对 180 万妇女的死亡负有责任。 此外，根据 2020 年的数据，高收入亚太地区的高权重指数年龄标准化死亡率最低，其次是大洋洲、北非、中东、中亚、撒哈拉以南非洲南部、中欧和东欧, 在撒哈拉以南非洲中部、中美洲和南美洲最高。 2020 年，高 BMI 导致全球 240 万人死亡。

同样，据泛美卫生组织称，全世界每年有 300 万人因饮酒死亡，还有数百万人失去健康。 饮酒与 200 多种健康状况有关，包括肝病、交通事故、暴力、几种癌症、心血管疾病、自杀、肺结核和艾滋病毒/艾滋病。 因此，上述数据表明，行为风险因素的增加导致心血管疾病的增加，从而在预测期内促进全球心臟修復系统的增长。

心臟手术的高成本将阻碍全球心臟修復系统市场的增长。

然而，在预测期内，心臟手术的高昂成本抑制了全球心臟修復系统市场的增长。 例如，印度三尖瓣修復手术的平均费用约为 3900 美元。

COVID-19 影响分析

心臟外科实践在 COVID-19 爆发期间，胸部疾病杂誌，2021 年 1 月：一份区域范围的调查论文发现所有医疗中心都采用了特定的患者和工作人员筛查方案。 重症监护病房（ICU）专用床位大幅减少至约30.0%，心臟手术室约22.2%，麻醉科5.8%，灌注科5.6%，护士4.8%，人员调动至其他科室。 心臟外科医生不会被重新分配到其他职责。 在全球范围内，随着机构和外科医生遵循指南并减少非紧急手术，成人心臟手术的数量从 2019 年的 667 多例大幅下降到 2020 年的 335 例。已证实 因此，心臟手术的减少和资源向紧急医疗需求的转移阻碍了市场增长，并对全球心臟修復系统市场产生了负面影响。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 市场活动
      • 心血管疾病患者人数增加
    • 约束因素
      • 心臟手术费用高
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 二尖瓣修復系统
  • 左心室修復系统

最终用户第 8 章

  • 医院
  • 专科诊所
  • 升序

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章按产品类型划分的市场规模分析及同比增长率分析（%）（英文

第 11 章市场规模分析和同比增长率分析（%）：按最终用户

第12章竞争格局竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第13章公司简介

  • 美敦力公司
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Abbott
  • BioVentrix Inc
  • NeoChord Inc
  • Edwards Lifesciences Corp
  • Virbac
  • Micro Port Scientific Corporation
  • CryoLife Inc.
  • Xeltis AG
  • Cook Medical

第14章 DataM

简介目录
Product Code: DMMD1800

Market Overview

The global cardiac restoration systems size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Cardiac restoration systems are employed for treating damaged and diseased heart valves. CVDs affect the heart and blood vessels, escalating conditions such as coronary heart diseases, stroke, etc., causing high-risk blood clots and fatty depositions in arteries. Cardiac restoration systems are used after any coronary artery bypass grafting remodeling the ventricular and initiating surgical anterior ventricular endocardial restoration (SAVER).

Market Dynamics

The growing number of cardiac diseases, geriatric population, market developments, and obese population is boosting the global cardiac restoration systems market.

The increasing number of cardiovascular disease cases is fueling the growth of the global cardiac restoration systems market.

Cardiovascular diseases include heart and blood vessel ailments, including coronary heart disorder, cerebrovascular disease, rheumatic heart disease, and other conditions. The growing cases of CVD are driving the global cardiac restoration systems. For instance, according to the American Heart Association, roughly 19.1 million deaths were caused by CVD globally in 2020. Globally, it was assessed that about 244.1 million individuals were living with ischemic heart disease (IHD), and it was more prevalent in males than in females (141.0 and 103.1 million people, respectively) in 2020. Also, according to the WHO, Cardiovascular diseases (CVDs) are the major cause of death worldwide, causing an estimated 17.9 million deaths annually.

The most important behavioral risk elements of heart disease and stroke are an unhealthful diet, physical laziness, tobacco use, and the harmful use of alcohol. The effects of behavioral risk factors may appear in patients as increased blood pressure, boosted blood glucose, extended blood lipids, and overweight and obesity. The upsurge in behavioral risk factors leads to increased CVDs globally. According to the American Heart Association's 2022 Heart Disease & Stroke Statistical Update Fact Sheet Global Burden of Disease, Tobacco (including smoking, secondhand smoke, and chewing tobacco) caused an estimated 8.1 million deaths globally in 2020 (6.3 million men and 1.8 million women). Also, based on 2020 data, age-standardized mortality rates attributable to high body mass index were lowest in high-income Asia Pacific and highest in Oceania, North Africa, the Middle East, Central Asia, southern sub-Saharan Africa, and locations in Central and Eastern Europe, Central sub-Saharan Africa, and Central Latin America. High BMI was attributed to 2.40 million global deaths in 2020.

Likewise, according to PAHO, globally, alcohol consumption contributes to 3 million deaths each year, and several millions of people lose health. The consumption of alcohol is causally linked to over 200 health conditions, including liver diseases, road injuries, violence, several types of cancers, cardiovascular diseases, suicides, tuberculosis, and HIV/AIDS. Thus, the mentioned data indicates that the increase in behavioral risk factors is leading to rising in cardiovascular diseases, thereby boosting the global cardiac restoration systems market growth in the forecast period.

The high cost of cardiac surgery will hamper the global cardiac restoration systems market growth.

However, the high cost of cardiac surgery is restraining the global cardiac restoration systems market during the forecast period. For example, the average tricuspid valve repair surgery cost in India is about 3900 USD.

COVID-19 Impact Analysis

According to a Cardiac surgery practice during the COVID-19 outbreak: a regionwide survey article published in January 2021 by the Journal of Thoracic Disease, all healthcare centers adopted specific protocols for screening patients and personnel. A significant reduction in the number of dedicated intensive care unit (ICU) beds was reduced by around 30.0%, and cardiac operating rooms were reduced by approximately 22.2%along with personnel relocation to other departments was disclosed such as anesthesiologists by 5.8%, perfusionists by 5.6%, and nurses by 4.8% among others. Cardiac surgeons were never reallocated to other services. Globally, we witnessed dramatically lower adult cardiac surgery case volumes, with 335 procedures in 2020 compared to over 667 procedures in 2019, as institutions and surgeons followed guidelines to curtail non-urgent operations. Thus, the reduction in cardiac procedures and relocation of resources toward urgent healthcare requirements hampered the market growth, negatively impacting the global cardiac restoration system market.

Segment Analysis

Mitral valve restoration systems are estimated to grow at the fastest CAGR during the forecast period (2022-2029).

The prevalence of rheumatic heart disease, the most common valvular heart disease (affecting approximately 41 million people), has been rising in developing nations, likely due to the expansion of the young adult population and the decrease in premature mortality that has resulted from improved access to antibiotics, microbiological testing, and echocardiography. Mitral regurgitation affects 24 million people worldwide, with great variability between and among nations. Primary mitral regurgitation arises due to myxomatous degeneration and mitral valve prolapse, largely due to genetic predispositions, while secondary mitral regurgitation accounts for 65% of cases and arises secondary to dilation and heart failure. MR is either equally prevalent between the sexes or slightly more prevalent in men than women. Mitral valve prolapse rates (MVP) are considerably higher in white patients than in black patients. MVP is the most common cardiac mitral valvular pathology worldwide, accounting for 2% to 3% of the total population. RHD remains prevalent in developing countries and is the most common cause of mitral valvular pathology resulting in hospital admissions. Acute MR can present with sudden onset of dyspnea and flash pulmonary edema, frequently secondary to myocardial infarction.

Chronic MR is often asymptomatic, though treatment is recommended before symptom onset. Furthermore, developments such as the first beating heart mitral valve repair on the West Coast were performed by Tom C. Nguyen, MD, chief of UC San Francisco's Division of Adult Cardiothoracic Surgery, and his surgical team in September 2021. The HARPOON™ Beating Heart Mitral Valve Repair System was used for the procedure as part of the RESTORE clinical trial. Thus, the mentioned data indicates that the mitral valve restoration systems will dominate the global cardiac restoration system in the forecasted period.

Geographical Analysis

The North American market is expected to grow at a high CAGR during the forecast period.

North America is estimated to hold a large market over the forecast period (2022-2029) because of the growing cases of cardiovascular conditions and the existence of key market players in this region. For instance, according to the CDC, a U.S. American dies every 34 seconds because of cardiovascular disease. Cardiovascular disease caused over 697,000 deaths in 2020. Moreover, the existence of key market players such as Abbott, BioVentrix Inc., CryoLife Inc., Edwards Lifesciences Corp, NeoChord Inc. among more, holding most of the global market, endure the growth of North America's cardiac restoration system market at a high CAGR throughout the forecast period. For instance, in March 2020, BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, reported that Ralph Stephan von Bardeleben, MD, of the University Medical Center of Mainz (Germany) has united with the European REVIVE-HF clinical trial of the Revivent TC Transcatheter Ventricular Enhancement System as co-principal investigator. Also, in January 2022, BioVentrix, Inc., a privately held medical device corporation concentrated on less intrusive treatments to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), acquired MateraCor, Inc., a firm focused on preventing the advancement of, and reversing, heart failure through the use of injectable alginate-based hydrogel.

Likewise, in February 2020, CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, was granted CE Mark for its On-X Ascending Aortic Prosthesis (AAP) indicated for the treatment of diseased, damaged, or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm, permitting it to resume dispersal in the European Union. Moreover, in September 2022, Edwards Lifesciences Corporation received FDA approval for its PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) in treating patients with degenerative mitral regurgitation (DMR). Thus, the data mentioned indicate that North America's market will grow at a high CAGR throughout the forecasted period.

Competitive Landscape

The growing focus on innovation keeps the global cardiac restoration systems market competitive. Abbott, BioVentrix Inc., NeoChord Inc., Edwards Lifesciences Corp, Virbac, Medtronic Inc., Micro Port Scientific Corporation, CryoLife Inc., Xeltis AG, and Cook Medical are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, in March 2022, Edwards Lifesciences received permission from the U.S. Food and Drug Administration (FDA) for the MITRIS RESILIA valve, a tissue valve replacement designed for the heart's mitral position.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. has CG Future Annuloplasty Ring and Band: The CG Future is an annuloplasty system for mitral valve repair, developed to predictably renovate the annulus to keep the apposition of the anterior and posterior leaflets.

The global cardiac restoration systems market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Market Events
      • 4.1.1.2. Increasing Number of Cardiovascular Disease Cases
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost Of Cardiac Surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Mitral Valve Restoration Systems *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Left Ventricular Restoration Systems

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Specialty Clinics
  • 8.4. ASCs

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics

10. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

11. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Medtronic Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Abbott
  • 13.3. BioVentrix Inc
  • 13.4. NeoChord Inc
  • 13.5. Edwards Lifesciences Corp
  • 13.6. Virbac
  • 13.7. Micro Port Scientific Corporation
  • 13.8. CryoLife Inc.
  • 13.9. Xeltis AG
  • 13.10. Cook Medical

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us